Keystone Therapeutics

Keystone Bio is a clinical-stage biotechnology company pioneering the field of oral-systemic medicine by targeting the keystone pathogen Porphyromonas gingivalis. The company's lead candidate, KB-001, is a precision monoclonal antibody designed to eradicate this bacterium from the oral cavity, preventing the systemic release of toxic gingipains that drive chronic inflammation. This inflammatory process is linked to several major diseases, including Alzheimer’s disease, cardiovascular disease, and type 2 diabetes. Keystone Bio is also developing a companion diagnostic, KB-Dx, to identify patients at high risk for these systemic conditions. By addressing the root cause of inflammation at its source in the mouth, the company aims to provide a transformative approach to treating and preventing chronic age-related diseases.